Stock listing

Dusseldorf:9EN Pharvaris N.V. Aktie

German listing (Dusseldorf) of Pharvaris N.V. · home listing NASDAQ:PHVS

Follow Pharvaris N.V. into a list and get an email when it puts out news.

Home listing price · NASDAQ:PHVS

$31.28 USD -0.27 (-0.9%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PHVS

Past year +29.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$30.43 – $31.99 USDNov 20, 2026
Volume
463,997 sharesNov 20, 2026
Market cap
$2.20B USDAt the close on Nov 20, 2026 · price × 70.20M shares outstanding
52-week range
$23.15 – $43.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$26.10M USDMedian day 627,797 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Pharvaris N.V. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PHVS · Home$31.28 USD-0.27 (-0.9%)463,997$31.41$31.99$30.43$31.55Close on Nov 20, 2026
Frankfurt:9EN€28.45 EUR-0.30 (-1.0%)—€28.30€28.65€27.65€28.75Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PHVS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$31.28-0.27-0.9%$31.41$31.99$30.43463,997
$31.55-0.73-2.3%$32.24$32.63$31.22390,162
$32.28-0.16-0.5%$32.00$32.42$31.29241,403
$32.44-0.92-2.8%$33.19$34.46$32.44307,781
$33.36-0.47-1.4%$33.79$34.28$32.85182,582
$33.83-0.35-1.0%$33.59$34.55$33.00376,267
$34.18+0.19+0.6%$34.01$34.73$33.82421,745
$33.99-0.48-1.4%$34.10$35.05$33.21745,421
$34.47+0.08+0.2%$34.80$35.47$34.05638,332
$34.39+1.86+5.7%$32.85$35.21$32.28405,106
$32.53-1.80-5.2%$34.33$34.66$32.53932,821
$34.33-0.45-1.3%$35.06$35.42$33.03311,376
$34.78+1.25+3.7%$33.90$35.30$33.90577,199
$33.530.000.0%$33.68$34.21$32.90633,053
$33.53-0.05-0.1%$33.48$33.94$33.051,481,526
$33.58+0.76+2.3%$32.84$33.62$32.70877,867
$32.82+0.87+2.7%$31.79$32.86$31.74381,071
$31.95+0.41+1.3%$31.62$32.34$31.59230,114
$31.54+0.13+0.4%$31.38$32.08$31.30347,674
$31.41+0.73+2.4%$31.57$32.12$30.25621,710
$30.68+0.02+0.1%$30.76$31.02$29.84347,236
$30.66-0.24-0.8%$31.22$31.50$30.55393,583
$30.90+1.13+3.8%$29.83$31.60$29.831,029,035
$29.77+2.03+7.3%$27.80$29.95$27.80917,081
$27.74-1.90-6.4%$29.50$29.54$27.681,307,641
$29.64-0.38-1.3%$30.20$30.85$29.23820,425
$30.020.000.0%$30.00$30.52$29.80400,428
$30.02-0.87-2.8%$30.68$31.21$29.99443,982
$30.89-0.21-0.7%$31.09$31.93$30.64646,018
$31.10-0.02-0.1%$31.14$31.96$31.09754,990
$31.12-0.56-1.8%$31.57$31.57$30.30628,231
$31.68+0.56+1.8%$30.97$32.32$30.58341,842
$31.12+0.63+2.1%$30.50$31.27$30.15778,389
$30.49-0.70-2.2%$31.19$31.47$30.15816,234
$31.19+0.18+0.6%$31.21$31.55$30.69591,391
$31.01-0.71-2.2%$31.74$31.98$30.90654,347
$31.72-0.010.0%$31.84$32.05$31.14839,837
$31.73-0.18-0.6%$31.93$32.34$31.23459,293
$31.91-0.11-0.3%$32.00$32.46$31.39753,331
$32.02-0.97-2.9%$33.08$33.62$31.96597,654
$32.99-0.08-0.2%$32.88$33.84$31.91949,002
$33.07-2.13-6.1%$35.19$35.31$32.87654,290
$35.20-0.82-2.3%$35.82$36.27$34.90588,601
$36.02-0.35-1.0%$36.33$36.88$35.50653,735
$36.37-1.63-4.3%$38.09$38.20$36.08580,260
$38.00+0.45+1.2%$37.81$38.93$37.601,137,444
$37.55-0.51-1.3%$38.12$38.38$37.00828,999
$38.06-0.80-2.1%$39.12$40.00$37.751,751,144
$38.86+0.84+2.2%$38.16$40.46$38.10998,004
$38.02+0.51+1.4%$38.13$40.60$37.471,449,491
$37.51-0.23-0.6%$37.60$39.03$37.001,324,987
$37.74-0.10-0.3%$38.26$39.18$37.051,427,371
$37.84+2.59+7.3%$40.96$43.25$37.606,328,168
$35.25-0.41-1.1%$35.36$36.39$35.21483,983
$35.66+0.49+1.4%$35.39$35.88$34.58357,063
$35.17+0.24+0.7%$35.05$35.97$34.04320,876
$34.93+0.32+0.9%$34.45$35.07$33.80394,435
$34.61-0.71-2.0%$35.31$35.73$34.13557,515
$35.32-1.68-4.5%$37.00$37.41$35.26479,029
$37.000.000.0%$37.00$37.49$36.30765,048
$37.00-0.23-0.6%$37.31$37.40$36.24448,941
$37.23-0.08-0.2%$37.32$38.00$36.69861,175
$37.31+1.04+2.9%$36.27$38.13$35.70691,824
$36.27-0.12-0.3%$36.61$36.93$36.12515,458
$36.39+0.12+0.3%$36.13$36.82$35.45627,797
Ticker
Dusseldorf:9EN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Pharvaris N.V. news

Pharvaris N.V. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 130 in all · newest Nov 12, 2026 · oldest 2021
Decks
21 decks · latest October 2026

Where Pharvaris N.V. is listed

ListingExchangeCountryCurrency
NASDAQ:PHVS · Home listingNASDAQUnited StatesUSD
gettex:9ENgettexGermanyEUR
LS Exchange:A2QNWSLS ExchangeGermanyEUR
Tradegate:9ENTradegateGermanyEUR
BOATS:PHVSBOATSUnited StatesUSD
Lang & Schwarz:A2QNWSLang & SchwarzGermanyEUR
Frankfurt:9ENFrankfurtGermanyEUR
Dusseldorf:9EN · This pageDusseldorfGermanyEUR
Munich:9ENMunichGermanyEUR
Stuttgart:9ENStuttgartGermanyEUR

Valuation

Price/book 7.5× against a median of 3.8×: 8th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.89B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
7.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.76

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Pharvaris N.V. · NASDAQ:PHVSUS$2.20BUS$1.89Bn/an/an/a7.5×n/a0.0×0.76
InSilico Medicine Cayman TopCo · HKEX:3696US$2.29BUS$1.70Bn/a30.3×n/a4.2×−626.5%0.0×n/a
SK bioscience Co.,Ltd. · KRX:302440US$2.26BUS$2.03Bn/a4.1×n/a1.7×−12.8%0.3×n/a
Arcus Biosciences, Inc. · NYSE:RCUSUS$2.25BUS$1.72Bn/a17.2×n/a6.3×−453.0%0.3×1.37
NewAmsterdam Pharma Company N.V. · NASDAQ:NAMSUS$2.20BUS$1.57Bn/a60.6×n/a3.5×−789.9%0.0×1.41
Lakefront Biotherapeutics · EURONEXT:LKFTUS$2.20B−US$260.8M3.4×−0.2×n/a0.6×60.2%0.0×n/a
BioArctic AB Class B · OMXSTO:BIOA_BUS$2.19BUS$2.00B212×20.4×90.0×11.1×10.5%0.0×n/a
Beam Therapeutics Inc. · NASDAQ:BEAMUS$2.16BUS$1.22Bn/a8.3×n/a2.3×−73.9%0.1×1.90
Celldex Therapeutics, Inc. · NASDAQ:CLDXUS$2.15BUS$1.50Bn/an/an/a3.3×n/a0.0×1.07
Palvella Therapeutics, Inc. · NASDAQ:PVLAUS$2.09BUS$1.85Bn/an/an/a10.6×n/a0.0×1.50
Regencell Bioscience Holdings Limited · NASDAQ:RGCUS$2.07BUS$2.06Bn/an/an/a155×n/a0.0×1.57
Median of the othersUS$2.19BUS$1.71B108×17.2×90.0×3.8×−73.9%0.0×1.46

Forecasts

11 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
58.19 USD · Analysts' mean
EPS, year to Dec 2026
-2.61 · 6 analysts

Team and board

Officers

OfficerRole
Berndt ModigChief Executive Officer, Director
David NassifChief Financial Officer & Chief Legal Officer
Peng LuPresident
Maggie BellerVice President, Head of Corporate and Investor Communications
Anna NijdamHead, Strategic Finance and Principal Accounting Officer
Anne LesageChief Early Development Officer
Annick DeschoolmeesterChief Human Resources Officer
Stefan AbeleChief Technical Operations Officer
Wim SouverijnsChief Commercial Officer

Board

DirectorRole
David MeekerChair of the Board
Viviane MongesDirector, Audit Chair
Berndt ModigChief Executive Officer, Director
Elisabeth BjörkDirector
Hans SchikanVice Chair of the Board
Robert GlassmanDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−1.0%
Q2 2026Aug 12, 2026 · Before open+5.9%
Q1 2026Apr 2, 2026 · Before open−3.0%
Q3 2025Nov 12, 2025 · Before open+7.0%
Q2 2025Aug 12, 2025 · After close+1.6%
Q1 2025May 13, 2025 · After close−0.3%
Q3 2024Nov 13, 2024 · After close+2.5%
Q2 2024Aug 14, 2024 · Before open−7.5%
Q1 2024May 8, 2024 · After close−1.3%
Q4 2023Mar 6, 2024 · Before open+5.9%
All 20 quarters
QuarterResultsShare move
Q3 2023Nov 2, 2023 · Before open+1.6%
Q2 2023Aug 7, 2023 · Before open−6.9%
Q1 2023May 8, 2023 · Before open+0.1%
Q3 2022Dec 8, 2022 · Before open+356.6%
Q2 2022Sep 12, 2022 · Before open−0.1%
Q1 2022May 11, 2022 · Before open−0.3%
Q4 2021Mar 29, 2022 · Before open+1.1%
Quarter to Sep 30, 2021Nov 10, 2021 · Before open−4.9%
Q2 2021Jul 30, 2021 · Before open+5.2%
Quarter to Mar 31, 2021May 26, 2021 · Before open0.0%

Open Events

Decks

DeckKindSlidesDate
HAEi Regional Conference Americas 2026Conference5 slidesOctober 2026
Technical Presentation (September 2026)Technical15 slidesSep 8, 2026
Investor Presentation (January 2026)Investor deck26 slidesJan 12, 2026
Technical Presentation (2026)Technical14 slides2026
Investor Presentation (January 2025)Investor deck113 slidesJan 13, 2025
Technical Presentation (2025)Technical12 slides2025
Investor Day (October 2024)Investor day32 slidesOct 23, 2024
Investor Presentation (September 2024)Investor deck54 slidesSep 5, 2024
Investor Presentation (September 2024)Investor deck37 slidesSeptember 2024
Investor Presentation (January 2024)Investor deck59 slidesJan 22, 2024
All 21 decks
DeckKindSlidesDate
Investor Presentation (December 2023)Investor deck40 slidesDec 6, 2023
Technical Presentation (December 2023)Technical25 slidesDec 6, 2023
Investor Presentation (March 2023)Investor deck45 slidesMar 8, 2023
Investor Presentation (February 2023)Investor deck47 slidesFeb 14, 2023
Investor Presentation (January 2023)Investor deck46 slidesJan 9, 2023
Technical Presentation (December 2022)Technical33 slidesDec 8, 2022
Investor Presentation (November 2022)Investor deck45 slidesNov 1, 2022
Investor Presentation (July 2022)Investor deck31 slidesJul 13, 2022
Investor Presentation (January 2022)Investor deck33 slidesJan 10, 2022
Technical Presentation (2021)Technical9 slides2021
Technical PresentationTechnical13 slides

Open Decks

Financings

RaiseDate
Public offering of ordinary shares and pre-funded warrants
Closed: US$201.2M raised · US$20 a share · Morgan Stanley +4
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Cantor (co-lead), Oppenheimer & Co. (co-lead), Van Lanschot Kempen (co-lead)
Use of proceeds: R&D for late-stage clinical programs, hiring a US sales and marketing team and commercialization, working capital and general corporate purposes
Jul 24, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$20.00 a share on Feb 4, 2021.

Price
US$20.00 a share
Shares offered
8,270,500 ordinary shares
Offering size
US$165.4 million
Underwriters' option
Up to 1,240,575 more shares
Underwriters
Morgan Stanley, BofA Securities, SVB Leerink, Oppenheimer & Co., Kempen & Co · In the order on the cover
Shares delivered
On or about Feb 9, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceNov 12, 2020
Filed publiclyJan 15, 2021
Amended twiceNewest Feb 1, 2021
Shares registered with an exchangeFeb 4, 2021
Declared effective by the SECFeb 4, 2021
Final prospectus, with the priceFeb 8, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Feb 8, 2021

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue00000000
Cost of revenue252.3K150.2K80.5K8.44K614
Gross profit-252.3K-150.2K-80.5K-8.44K-614
Research and development124.5M98.6M65.6M57.4M35.8M19.5M5.68M3.65M
Selling, general and administrative45.3M46.7M31.3M29.0M18.3M5.50M2.33M668.1K
Operating income-173.7M-132.4M-99.8M-75.7M-42.7M-26.1M-8.03M-4.31M
Depreciation and amortization418.4K269.6K257.6K152.9K77.4K7.40K5490
EBITDA-173.3M-132.1M-99.6M-75.5M-42.6M-26.1M-8.03M-4.31M
Interest expense20.1K16.1K267.5K92.5K16.9K380
Income before tax-173.7M-132.4M-99.8M-75.7M-42.7M-26.1M-8.03M-4.31M
Income tax1.99M1.83M1.05M679.1K70.1K-83.3K00
Net income-175.7M-134.2M-100.9M-76.3M-42.7M-26.0M-8.03M-4.31M
Earnings per share, basic-2.97-2.48-2.63-2.27-1.40-0.85-0.25-0.14
Earnings per share, diluted-2.97-2.48-2.63-2.27-1.40

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents291.7M280.7M391.2M161.8M209.4M98.6M20.3M5.39M4.80M
Short-term investments322.6K
Receivables4.55M2.94M1.04M382.5K700.1K569.6K210.8K26.4K1.06K
Inventory-322.6K4.04M1.51M540.7K
Current assets299.2M289.4M397.9M166.8M211.6M101.0M20.6M5.43M4.80M
Property, plant and equipment642.5K667.0K223.7K193.5K108.1K48.5K12.9K0
Total assets301.5M291.4M398.7M167.7M212.1M101.1M20.6M5.43M4.80M
Accounts payable5.11M4.56M2.91M6.69M2.49M830.9K517.8K246.4K60.5K
Current liabilities29.6M23.0M14.6M18.2M6.99M5.31M1.92M481.3K138.8K
Total debt776.8K861.5K238.9K436.8K250.2K
Total liabilities30.2M23.6M14.6M18.5M7.14M5.31M1.92M481.3K138.8K
Shareholders' equity271.3M267.8M384.0M149.3M205.0M95.8M18.7M4.95M4.66M
Shares outstanding59.2M54.0M38.4M33.6M30.4M30.5M31.8M31.8M30.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-137.1M-120.1M-93.0M-67.2M-44.6M-21.5M-6.68M-3.92M
Capital spending-164.6K-538.1K-90.0K-124.3K-130.0K-43.0K-13.5K0
Free cash flow-137.2M-120.7M-93.1M-67.3M-44.7M-21.5M-6.69M-3.92M
Cash from investing-164.6K-538.1K-90.0K-124.3K-130.0K-43.0K-13.5K0
Cash from financing160.6M2.68M325.4M8.65M143.7M101.2M21.6M4.51M
Change in cash23.4M-118.0M232.3M-58.6M98.9M79.7M14.9M590.2K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
6-K · Report of a foreign issuerNov 12, 2026Current reportSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
144 · Notice of proposed saleSep 23, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 23, 2026Insider tradeSEC
144/A · Notice of proposed sale, amendedSep 22, 2026Other filingsSEC
144 · Notice of proposed saleSep 22, 2026Other filingsSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
144 · Notice of proposed saleSep 21, 2026Other filingsSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
144 · Notice of proposed saleSep 10, 2026Other filingsSEC
144 · Notice of proposed saleSep 9, 2026Other filingsSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
6-K · Report of a foreign issuerSep 8, 2026Current reportSEC
6-K · Report of a foreign issuerSep 8, 2026Current reportSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
6-K · Report of a foreign issuerAug 12, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 31, 2026Big-stake noticeSEC
4 · Change in ownershipJul 15, 2026Insider tradeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
144 · Notice of proposed saleJul 13, 2026Other filingsSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
6-K · Report of a foreign issuerJun 26, 2026Current reportSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
6-K · Report of a foreign issuerJun 11, 2026Current reportSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
144 · Notice of proposed saleMay 22, 2026Other filingsSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4/A · Change in ownership, amendedMay 22, 2026Insider tradeSEC
144 · Notice of proposed saleMay 21, 2026Other filingsSEC
144 · Notice of proposed saleMay 21, 2026Other filingsSEC
144 · Notice of proposed saleMay 21, 2026Other filingsSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
144 · Notice of proposed saleMay 20, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedMay 20, 2026Other filingsSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
6-K · Report of a foreign issuerMay 12, 2026Current reportSEC
6-K · Report of a foreign issuerMay 11, 2026Current reportSEC
424B5 · ProspectusMay 8, 2026Offer documentSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
144 · Notice of proposed saleApr 16, 2026Other filingsSEC
4 · Change in ownershipApr 14, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
144 · Notice of proposed saleApr 8, 2026Other filingsSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
3/A · Initial statement of ownership, amendedApr 3, 2026Insider tradeSEC
20-F · Annual reportApr 2, 2026Annual reportSEC
6-K · Report of a foreign issuerApr 2, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJan 12, 2026Current reportSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
6-K · Report of a foreign issuerDec 3, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2025Current reportSEC
POSASRSep 23, 2025Other filingsSEC
6-K · Report of a foreign issuerSep 8, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerAug 12, 2025Current reportSEC
UPLOAD · Letter from the SECAug 11, 2025Other filingsSEC
CORRESP · Letter to the SECAug 6, 2025Other filingsSEC
6-K · Report of a foreign issuerJul 24, 2025Current reportSEC
UPLOAD · Letter from the SECJul 24, 2025Other filingsSEC
424B5 · ProspectusJul 24, 2025Offer documentSEC
FWP · Free writing prospectusJul 22, 2025Offer documentSEC
424B5 · ProspectusJul 22, 2025Offer documentSEC
144 · Notice of proposed saleJul 14, 2025Other filingsSEC
144 · Notice of proposed saleJul 11, 2025Other filingsSEC
6-K · Report of a foreign issuerJul 10, 2025Current reportSEC
6-K · Report of a foreign issuerJun 27, 2025Current reportSEC
6-K · Report of a foreign issuerJun 10, 2025Current reportSEC
6-K · Report of a foreign issuerMay 13, 2025Current reportSEC
6-K · Report of a foreign issuerApr 7, 2025Current reportSEC
20-F · Annual reportApr 7, 2025Annual reportSEC
6-K · Report of a foreign issuerJan 13, 2025Current reportSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
6-K · Report of a foreign issuerNov 13, 2024Current reportSEC
144 · Notice of proposed saleOct 31, 2024Other filingsSEC
144 · Notice of proposed saleOct 24, 2024Other filingsSEC
6-K · Report of a foreign issuerSep 25, 2024Current reportSEC
6-K · Report of a foreign issuerSep 23, 2024Current reportSEC
144 · Notice of proposed saleSep 20, 2024Other filingsSEC
144 · Notice of proposed saleSep 19, 2024Other filingsSEC
144 · Notice of proposed saleSep 19, 2024Other filingsSEC
144 · Notice of proposed saleSep 19, 2024Other filingsSEC
144 · Notice of proposed saleSep 19, 2024Other filingsSEC
144 · Notice of proposed saleSep 16, 2024Other filingsSEC
6-K · Report of a foreign issuerSep 5, 2024Current reportSEC
144 · Notice of proposed saleAug 30, 2024Other filingsSEC
144 · Notice of proposed saleAug 27, 2024Other filingsSEC
144 · Notice of proposed saleAug 26, 2024Other filingsSEC
144 · Notice of proposed saleAug 19, 2024Other filingsSEC
144 · Notice of proposed saleAug 19, 2024Other filingsSEC
144 · Notice of proposed saleAug 16, 2024Other filingsSEC
144 · Notice of proposed saleAug 15, 2024Other filingsSEC
144 · Notice of proposed saleAug 14, 2024Other filingsSEC
6-K · Report of a foreign issuerAug 14, 2024Current reportSEC
144 · Notice of proposed saleAug 13, 2024Other filingsSEC
6-K · Report of a foreign issuerJun 28, 2024Current reportSEC
144 · Notice of proposed saleJun 12, 2024Other filingsSEC
144 · Notice of proposed saleJun 11, 2024Other filingsSEC
6-K · Report of a foreign issuerJun 11, 2024Current reportSEC
144 · Notice of proposed saleJun 10, 2024Other filingsSEC
6-K · Report of a foreign issuerJun 4, 2024Current reportSEC
144 · Notice of proposed saleMay 24, 2024Other filingsSEC
144 · Notice of proposed saleMay 22, 2024Other filingsSEC
144 · Notice of proposed saleMay 21, 2024Other filingsSEC
6-K · Report of a foreign issuerMay 8, 2024Current reportSEC
144 · Notice of proposed saleApr 23, 2024Other filingsSEC

This page holds 200 of 332 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Pharvaris N.V.’s releases · as of Jul 24, 2025

Common shares
70,204,506
Fully diluted
70,204,506

Fully diluted

LineShares
Common shares70,204,506

Share count over time

CountShares
Nov 22, 202670,204,506

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
Fidelity Growth Company Fund1.37MUS$41.5MMay 31, 2026
Vanguard Health Care Fund1.17MUS$38MJul 31, 2026
Select Health Care Portfolio800KUS$24.1MMay 31, 2026
Fidelity Small Cap Growth Fund645KUS$21MJul 31, 2026
Fidelity Advisor Health Care Fund400KUS$13MJul 31, 2026
Fidelity Growth Company K6 Fund398KUS$12MMay 31, 2026
Fidelity Series Growth Company Fund339KUS$10.2MMay 31, 2026
Fidelity Small Cap Growth K6 Fund326KUS$10.6MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.282KUS$9.75MJun 30, 2026
iShares Biotechnology ETF207KUS$7.17MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Select Biotechnology Portfolio148KUS$4.46MMay 31, 2026
Vanguard International Explorer Fund133KUS$4.33MJul 31, 2026
VIP Health Care Portfolio128KUS$4.43MJun 30, 2026
iShares Core MSCI EAFE ETF128KUS$4.17MJul 31, 2026
The Hartford Healthcare Fund123KUS$4.03MJul 31, 2026
iShares MSCI EAFE Small-Cap ETF79,447US$2.59MJul 31, 2026
ALPS Medical Breakthroughs ETF66,026US$1.99MMay 31, 2026
The Hartford Small Company Fund42,941US$1.4MJul 31, 2026
Fidelity Nasdaq Composite Index Fund40,106US$1.21MMay 31, 2026
iShares MSCI Netherlands ETF39,113US$1.18MMay 31, 2026
Nationwide International Small Cap Fund38,406US$1.25MJul 31, 2026
Hartford Small Company Hls Fund27,889US$964KJun 30, 2026
Fidelity Nasdaq Composite Index ETF26,840US$809KMay 31, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF23,720US$820KJun 30, 2026
T. Rowe Price Health Sciences Portfolio20,584US$712KJun 30, 2026
International Opportunities Fund18,837US$568KMay 31, 2026
Hartford Healthcare Hls Fund17,554US$607KJun 30, 2026
Small Cap Stock Trust17,545US$607KJun 30, 2026
Fidelity Total International Index Fund13,366US$436KJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account12,654US$438KJun 30, 2026
MassMutual Small Cap Growth Equity Fund12,071US$417KJun 30, 2026
Virtus Biotech Clinical Trials Etf10,118US$330KJul 31, 2026
Lazard US Small Cap Equity Select Portfolio8,477US$293KJun 30, 2026
Tiff Multi-Asset Fund7,692US$266KJun 30, 2026
Lazard Global Small Cap Equity Portfolio6,862US$237KJun 30, 2026
Multi-Manager U.S. Small Cap Equity Fund6,801US$211KApr 30, 2026
Health Sciences Trust6,668US$231KJun 30, 2026
Fidelity SAI International Small Cap Index Fund5,751US$188KJul 31, 2026
Thrivent International Equity Portfolio5,020US$174KJun 30, 2026
EQ/T.Rowe Price Health Sciences Portfolio4,824US$167KJun 30, 2026
MML VIP Wellington Small Cap Growth Equity Fund4,718US$163KJun 30, 2026
Invesco Nasdaq Biotechnology ETF3,443US$104KMay 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio3,300US$114KJun 30, 2026
Parametric International Equity Fund3,200US$104KJul 31, 2026
Thrivent International Equity Fund2,957US$96,457Jul 31, 2026
ProShares Ultra Nasdaq Biotechnology2,367US$71,389May 31, 2026
iShares MSCI Europe Small-Cap ETF2,247US$73,297Jul 31, 2026
Victory Science & Technology Fund1,659US$54,117Jul 31, 2026
iShares MSCI World Small-Cap ETF1,399US$42,194May 31, 2026
Virtus AlphaSimplex Global Alternatives Fund752US$26,004Jun 30, 2026

This page holds 50 of 57 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Monges Viviane
Director
Sale11,969USD 33.05US$396KSep 23, 2026
Schikan Johannes Gerardus Christiaan Petrus
Director
Sale800USD 36.19US$28,952Sep 22, 2026
Nassif David W.
Officer: CFO / CLO
Sale6,000USD 36.47US$219KSep 21, 2026
Lesage Anne
Officer: Chief Early Development
Sale20,000USD 38.27US$765KSep 17, 2026
Glassman Robert
Director
Sale14,493USD 38.56US$559KSep 17, 2026
Bjork Elisabeth
Director
Sale52,500USD 37.89US$1.99MSep 17, 2026
Schikan Johannes Gerardus Christiaan Petrus
Director
Sale200,000USD 35.00US$7MSep 17, 2026
Lu Peng
Officer: President
Sale100,000USD 35.00US$3.5MSep 17, 2026
Glassman Robert
Director
Sale8,667USD 38.27US$332KSep 15, 2026
Abele Stefan Andreas
Officer: Chief Technical Ops Officer
Sale45,000USD 38.14US$1.72MSep 15, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Abele Stefan Andreas
Officer: Chief Technical Ops Officer
Sale1,400USD 39.24US$54,936Sep 15, 2026
Souverijns Wim
Officer: Chief Commercial Officer
Sale6,090USD 38.99US$237KSep 15, 2026
Souverijns Wim
Officer: Chief Commercial Officer
Sale20,000USD 39.31US$786KSep 14, 2026
Modig Berndt
Director, Officer: Chief Executive Officer
Sale2,291USD 39.40US$90,265Sep 14, 2026
Lu Peng
Officer: President
Sale15,000USD 40.13US$602KSep 11, 2026
Lesage Anne
Officer: Chief Early Development
Sale30,000USD 38.30US$1.15MSep 10, 2026
Glassman Robert
Director
Sale8,000USD 37.55US$300KSep 9, 2026
Lu Peng
Officer: President
Sale15,000USD 40.68US$610KSep 8, 2026
Modig Berndt
Director, Officer: Chief Executive Officer
Sale2,292USD 34.77US$79,693Aug 14, 2026
Modig Berndt
Director, Officer: Chief Executive Officer
Sale2,292USD 34.97US$80,151Jul 13, 2026
Lesage Anne
Officer: Chief Early Development
Sale27,872USD 35.48US$989KJun 30, 2026
Lesage Anne
Officer: Chief Early Development
Sale30,703USD 35.49US$1.09MJun 30, 2026
Schikan Johannes Gerardus Christiaan Petrus
Director
Sale30,712USD 35.49US$1.09MJun 30, 2026
Lesage Anne
Officer: Chief Early Development
Sale2,300USD 35.12US$80,776Jun 29, 2026
Lesage Anne
Officer: Chief Early Development
Sale8,300USD 35.05US$291KJun 29, 2026
Lesage Anne
Officer: Chief Early Development
Sale6,997USD 35.05US$245KJun 29, 2026
Schikan Johannes Gerardus Christiaan Petrus
Director
Sale6,888USD 35.05US$241KJun 29, 2026
Schikan Johannes Gerardus Christiaan Petrus
Director
Sale2,400USD 35.10US$84,240Jun 29, 2026
Lu Peng
Officer: Chief Medical Officer
Sale14,700USD 34.00US$500KJun 26, 2026
Lu Peng
Officer: Chief Medical Officer
Sale11,600USD 34.45US$400KJun 25, 2026
Lu Peng
Officer: Chief Medical Officer
Sale3,400USD 35.09US$119KJun 25, 2026
Lesage Anne
Officer: Chief Early Development
Sale2,300USD 35.12US$80,776Jun 25, 2026
Lu Peng
Officer: Chief Medical Officer
Sale300USD 34.00US$10,200Jun 18, 2026
Modig Berndt
Director, Officer: Chief Executive Officer
Sale2,191USD 31.05US$68,031Jun 15, 2026
Modig Berndt
Director, Officer: Chief Executive Officer
Sale100USD 31.46US$3,146Jun 15, 2026
Nijdam Anna
Officer: Principal Accounting Officer
Sale2,670USD 30.87US$82,423Jun 4, 2026
Nijdam Anna
Officer: Principal Accounting Officer
Sale5,501USD 30.74US$169KMay 22, 2026
Nassif David W.
Officer: CFO / CLO
Sale10,000USD 30.31US$303KMay 21, 2026
Nijdam Anna
Officer: Principal Accounting Officer
Sale1,829USD 30.60US$55,967May 21, 2026
Monges Viviane
Director
Sale9,667USD 30.29US$293KMay 21, 2026
Bjork Elisabeth
Director
Sale10,000USD 29.32US$293KMay 20, 2026
Modig Berndt
Director, Officer: Chief Executive Officer
Sale2,292USD 29.22US$66,972May 18, 2026
Souverijns Wim
Officer: Chief Commercial Officer
Sale10,000USD 29.92US$299KMay 15, 2026
Abele Stefan Andreas
Officer: Chief Technical Ops Officer
Sale8,748USD 29.82US$261KMay 15, 2026
Glassman Robert
Director
Sale5,333USD 29.83US$159KMay 15, 2026
Glassman Robert
Director
Sale4,667USD 29.82US$139KMay 15, 2026
Lu Peng
Officer: Chief Medical Officer
Sale14,023USD 30.16US$423KMay 1, 2026
Lu Peng
Officer: Chief Medical Officer
Sale143USD 31.00US$4,433May 1, 2026
Lu Peng
Officer: Chief Medical Officer
Sale15,000USD 30.24US$454KApr 30, 2026
Lesage Anne
Officer: Chief Early Development
Sale3,700USD 30.26US$112KApr 30, 2026

This page holds 50 of 68 trades. Open Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Meeker
Other companies: Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); Trevi Therapeutics, Inc. (Chairman · Since at least May 7, 2019); Rhythm Pharmaceuticals, Inc. (Chairman, President, and Chief Executive Officer · Since at least Oct 4, 2017); Turmeric Acquisition Corp (Director · Oct 15, 2020 – Oct 15, 2020 · Past); MyoKardia Inc (Director · Apr 17, 2017 – Nov 17, 2020 · Past); Savient Pharmaceuticals Inc (Director · Jan 7, 2013 – Jan 7, 2013 · Past)
Chair of the Board · Since at least Mar 18, 2026
Berndt Modig
Other companies: Sio Gene Therapies Inc (Director · Apr 29, 2016 – Apr 15, 2021 · Past)
Chief Executive Officer, Director · Since at least Mar 17, 2026
Elisabeth Björk
Other companies: Rocket Pharmaceuticals, Inc. (Director · Since at least Apr 20, 2020)
Director · Since at least Mar 18, 2026
Viviane Monges
Other companies: ADC Therapeutics SA (Non-Executive Director · Since at least Jun 1, 2026)
Director · Since at least May 21, 2026
Anna NijdamHead, Strategic Finance and Principal Accounting Officer · Since at least Apr 1, 2026
Anne LesageChief Early Development Officer · Since at least Mar 18, 2026
Annick DeschoolmeesterChief Human Resources Officer · Since at least Mar 18, 2026
David NassifChief Financial Officer & Chief Legal Officer · Since at least May 21, 2026
Hans SchikanVice Chair of the Board · Since at least Nov 5, 2026
Johannes Gerardus Christiaan Petrus SchikanDirector · Since at least Mar 17, 2026
All 16 people
PersonSeat
Maggie BellerVice President, Head of Corporate and Investor Communications · Since at least Sep 8, 2026
Peng LuPresident · Since at least Mar 18, 2026
Peng LuPresident · Since at least Oct 5, 2026
Robert GlassmanDirector · Since at least Mar 17, 2026
Stefan AbeleChief Technical Operations Officer · Since at least Mar 18, 2026
Wim SouverijnsChief Commercial Officer · Since at least Jan 13, 2025

Open People

Log in to ask 6ix AI your own questions about Pharvaris N.V.